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Abstract
Background: Dietary supplement use in both human and animals to augment overall health continues to increase
and represents a potential health risk due to the lack of safety regulations imposed on the manufacturers. Because
there are no requirements for demonstrating safety and efficacy prior to marketing, dietary supplements may
contain potentially toxic contaminants such as hepatotoxic microcystins produced by several species of blue-green
algae.
Case presentation: An 11-year-old female spayed 8.95 kg Pug dog was initially presented for poor appetite,
lethargy polyuria, polydipsia, and an inability to get comfortable. Markedly increased liver enzyme activities were
detected with no corresponding abnormalities evident on abdominal ultrasound. A few days later the liver enzyme
activities were persistently increased and the dog was coagulopathic indicating substantial liver dysfunction. The
dog was hospitalized for further care consisting of oral S-adenosylmethionine, silybin, vitamin K, and ursodeoxycholic
acid, as well as intravenous ampicillin sodium/sulbactam sodium, dolasetron, N-acetylcysteine, metoclopramide, and
intravenous fluids. Improvement of the hepatopathy and the dog’s clinical status was noted over the next three days.
Assessment of the dog’s diet revealed the use of a commercially available blue-green algae dietary supplement for
three-and-a-half weeks prior to hospitalization. The supplement was submitted for toxicology testing and revealed
the presence of hepatotoxic microcystins (MCs), MC-LR and MC-LA. Use of the supplement was discontinued and
follow-up evaluation over the next few weeks revealed a complete resolution of the hepatopathy.
Conclusions: To the authors’ knowledge, this is the first case report of microcystin intoxication in a dog after using
a commercially available blue-green algae dietary supplement. Veterinarians should recognize the potential harm
that these supplements may cause and know that with intervention, recovery is possible. In addition, more prudent
oversight of dietary supplement use is recommended for our companion animals to prevent adverse events/intoxications.
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Background
Dietary supplement use to augment overall health in
humans is not a new phenomenon. More than half of all
adults in the United States currently take one or more
dietary supplements [1]. Extension of this practice to
household pets is also commonplace. More than a fourth
of all households in one study reported feeding supple-
ments to their dogs [2]. More alarming is that the dietary
supplement industry is largely self-regulated, although
there are some safeguards in place following the passage
of the 1994 Dietary Supplement Health and Education
Act (DSHEA) by the United States Food and Drug Ad-
ministration (FDA) [3]. Good manufacturing practices
and adverse event reporting are just a few of the safe-
guards; however, there is no premarket review of safety
[4]. Thus, many consumers falsely assume that dietary
supplements are screened for safety prior to marketing.
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Reports of contamination with various adulterants
including microcystins [5, 6] highlight the need for vigi-
lance in daily use of these products in humans and
animals.
Dietary supplements containing blue-green algae have
been marketed to the public since the early 1980’s [7].
Spirulina platensis and Aphanizomenon flos aquae (A.
flos aquae) are two of the most common species either
grown under controlled conditions or collected from the
natural environment. In the case of A. flos aquae, the
Upper Klamath Lake in Oregon is one of the most used
sources for harvesting these blue-green algae. Unfortu-
nately, the open, natural environment also allows other
potentially toxic cyanobacteria, such as Microcystis aeru-
ginosa to flourish. Thus, contamination of the A. flos
aquae during harvesting can and does occur [8]. Fur-
thermore, contamination of dietary supplements contain-
ing naturally harvested A. flos aquae with microcystins
has been documented [5, 7, 9] and poses a health risk to
the consumer.
Microcystins are potent cyclic peptides produced by
certain species of cyanobacteria and are quite resistant
to degradation. Currently, over 100 congeners have been
identified [10, 11], with MC-LR (abbreviated for com-
mon amino acids leucine and arginine at positions 2 and
4, respectively) [12] being the most consistently identi-
fied and potentially potent congener. MC-LR and several
other congeners are known to inhibit protein phosphat-
ase leading to acute liver failure [13]. However, due to
their diverse nature, a complete understanding of the
acute and chronic effects of the MCs is lacking. Conge-
ners other than MC-LR have been linked with animal in-
toxications [14] and effects on other organs have been
noted [15] raising the possibility that human and animal
risk may be underestimated. Intoxication or adverse ef-
fects from microcystin contaminated dietary supple-
ments have not been reported in humans or animals.
The current case report describes the discernible clinical
and toxicological findings in a dog following the use of a
commercially available blue-green algae dietary supple-
ment and illustrates the risks involved when using un-
regulated over-the-counter products.
Case presentation
An 11-year-old female spayed Pug dog, weighing 8.95 kg
with a body condition score of 6/9, initially was pre-
sented to her veterinarian for poor appetite, lethargy,
polyuria, polydipsia, and an inability to get comfortable.
Serum biochemical abnormalities included high alkaline
phosphatase (ALP) (414 U/L, reference (ref) range 23–212
U/L) and alanine aminotransferase (ALT) (>1000 U/L, ref
range 10–100 U/L) activities (Table 1) and subsequently,
the dog was referred to Red Bank Veterinary Hospital
(RBVH) (New Jersey) for an abdominal ultrasound. Add-
itional abnormalities found at initial presentation included
thrombocytosis (527 K/μL, ref range 175–500 K/μL) and
isosthenuria (1.007, ref range 1.015-1.050). Five months
prior to presentation, the dog’s liver enzyme concentrations
were within the reference range (Table 1). Past medical his-
tory included a rectal sarcoma excised approximately
32 months prior followed by chemotherapy (4 treatments
of doxorubicin) with no evidence of recurrence at the time
of presentation. In addition, the dog was treated for pan-
creatitis as an outpatient 5 months prior; pancreatitis was
diagnosed by abdominal ultrasound and results of serum
canine pancreas-specific lipase. Furthermore, three months
prior to presentation, the dog was treated for urolithiasis
by a cystotomy (struvite). The dog had concurrent prob-
lems including a collapsing trachea (managed with hydro-
codone 1.25 mg, PO, q 12 h), keratoconjunctivitis sicca
(treated with ophthalmic tacrolimus aqueous 0.02 % solu-
tion 1 drop, OU, q 12 h and artificial tears), and urinary in-
continence (controlled with phenylpropanolamine 25 mg,
PO, q 12 h). The owner prepared home-cooked meals for
the dog since the episode of pancreatitis 5 months prior
which included a combination of cooked chicken breast,
turkey breast, or ground beef with peas, carrots, and white
potato. On initial physical examination, the dog was alert,
eupneic, dehydrated, and the abdomen palpated as
non-painful. Stertor and pigmentary keratitis, common
to this breed, were also noted. In-house assessment of
ALT activity was significantly high (2620 U/L, ref range
10–100 U/L). On abdominal ultrasound, the liver ap-
peared diffusely normal with smooth margins. There
was no evidence of pancreatitis or free abdominal fluid.
Table 1 Serial serum biochemistry and coagulation panel results at various time points after initial presentationa
Parameter 5 months prior Day 1 Day 4 Day 5 Day 6 Day 7 Day 14 Day 40 Reference Range
ALT (U/L) 50 2620 2054 838 704 620 181 42 10-100
AST (U/L) 503 208 167 192 50 39 0-50
ALP (U/L) 110 414 753 277 402 640 308 119 23-212
Total bilirubin (mg/dL) 0.4 1.1 1.4 0.8 0.6 0.4 0.4 0-0.9
PT (sec) 41 16 14 11-17
PTT (sec) >300 97 72-102
aALT = alanine aminotransferase; AST = aspartate aminotransferase; ALP = alkaline phosphatase; PT = prothrombin time; PTT = partial thromboplastin time
Bautista et al. BMC Veterinary Research  (2015) 11:136 Page 2 of 6
Therefore, no cause for the markedly high ALT activity
was identified. The owner elected outpatient care con-
sisting of the administration of PlasmaLyte A (200 ml,
SC, q 24 h), amoxicillin trihydrate/clavulanate potas-
sium (125 mg, PO, q 12 h) and maropitant (8 mg, PO,
q 24 h). Three days later, the dog was presented again
to RBVH for continued lethargy and inappetence, as
well as one episode of vomiting. Serum biochemistry
abnormalities included high ALT, ALP and aspartate
aminotransferase (AST) activities (Table 1), prompting
assessment of coagulation. Both prothrombin time (PT)
and partial thromboplastin time (PTT) were signifi-
cantly prolonged at 41 sec and >300 sec, respectively
(ref range 11–17 s and 72–102 s). The dog was hospi-
talized for supportive care due to her clinical signs, serum
biochemical abnormalities and coagulopathy. Supportive
care was initiated consisting of S-adenosylmethionine with
silybin (225 mg with 24 mg, PO, q 24 h), ursodeoxycholic
acid (90 mg, PO, q 24 h), ampicillin sodium/sulbactam so-
dium (195 mg, IV, q 8 h), dolasetron (5.3 mg, IV, q 24 h),
N-acetylcysteine (140 mg/kg loading dose; 50 mg/kg, IV, q
6 h ×3 days), metoclopramide (1 mg/kg/day, IV, CRI),
vitamin K1 (26 mg, SC, q 24 h) once daily and IV fluid
therapy, consisting of PlasmaLyte A supplemented with B-
complex vitamins. Clinical and serum biochemical im-
provement of the hepatopathy were noted over the next
3 days of hospitalization (Table 1).
Scrupulous assessment of the dog’s home prepared
diet revealed the use of a dietary supplement for the pre-
vious three-and–a-half weeks. The supplement consisted
of 100 % certified organic Aphanizomenon flos aquae
and a suggested dose for a dog weighing 13.6 kg and
under was 1 of the provided measurement scoop (equal
to 1 gram) of powder one or more times daily. The dog’s
owner had been administering less than a 1 scoop of the
supplement once daily. The owner was additionally pro-
viding a veterinary glucosamine and chondroitin supple-
ment per manufacture recommendations. The powdered
blue-green algae dietary supplement was submitted for
toxicology testing due to concern for the possible pres-
ence of hepatotoxic microcystins. To evaluate the func-
tional toxicity of the powder, a protein phosphatase
inhibition assay (PPIA) was performed after one gram of
powder was dissolved in water, sonicated, and centri-
fuged to obtain a crude extract. To determine if an
increasing dose of powder resulted in a dose-dependent
increase in toxicity (protein phosphatase inhibition)
PPIA data was log transformed and analyzed by linear
regression using the statistical software R. As concentra-
tions of powder extract were increased, protein phos-
phatase activity significantly decreased (slope −0.0186,
p < 0.001, Fig. 1). To evaluate the presence of 4 specific
MC congeners for which analytical standards are avail-
able (MC-LR, −LA, −RR, −YR), samples of powder
were extracted using methanol and analyzed by liquid
chromatography-mass spectrometry/mass spectrometry.
The powder contained 166 ng/g of MC-LR and 962 ng/g
of MC-LA; none of the other MC congeners were de-
tected in the powder.
Use of the blue-green algae supplement was discontin-
ued just prior to hospitalization. The dog was sent home
after 4 days of hospitalization (Day 7) on amoxicillin trihy-
drate/clavulanate potassium (125 mg, PO, q 12 h × 7 days),
vitamin K1 (25 mg, PO, q 24 h × 5 days), S-
adenosylmethionine with silybin (225 mg with 24 mg, PO,
q 24 h), vitamin E (200 IU, PO, q 24 h), ursodeoxycholic
acid (90 mg, PO, q 24 h × 7 days), and milk thistle
(150 mg, PO, q 24 h). While hospitalized, the dog con-
sumed a combination of canned or boiled chicken breast
with white rice and was discharged with recommenda-
tions to continue these foods short term before transition
to a complete and balanced home prepared maintenance
diet. Two weeks following discharge, the dog was started
on a complete and balanced home prepared diet (34 %
metabolizable energy (ME) protein, 19 % ME fat, 47 % ME
carbohydrate) using ingredients such as cooked chicken
breast, turkey breast, or ground beef with white potato,
and mixed vegetables formulated by a board-certified vet-
erinary nutritionist. Follow-up evaluation over the next
few weeks revealed a complete resolution of clinical signs
and serum biochemical abnormalities (Table 1) and there-
fore, the use of liver support supplements (S-adenosyl-

































Fig. 1 Change in PP1 activity. One gram of blue-green algae
supplement powder was dissolved in water and sonicated on ice,
centrifuged, and supernatant was used to determine the presence
of protein phosphatase 1 (PP1) inhibitors. The y-axis is the log
(exposed PP1 rate/control PP1 rate) and the x-axis is the volume
of extracted water from the powder in μL tested. Each protein
phosphatase inhibition assay (PPIA, n = 4), analyzed in triplicate
with a substrate blank, is represented as one point, and the linear
model with a 95 % confidence interval is displayed with the data.
As the amount of extract increases, the activity of PP1 significantly
decreases compared to control, with a p value of 5.9 × 10−8
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discontinued. Urine analysis 5 months following discharge
revealed improved urine concentrating ability (urine spe-
cific gravity 1.017). At approximately one-year follow-up,
the dog was healthy with no recurrence of clinical signs or
laboratory abnormalities indicative of hepatic disease or
dysfunction.
Discussion
The current case study confirms a case of microcystin
poisoning in a dog following the use of a blue-green
algae dietary supplement and highlights the importance
of the toxic potential of these dietary supplements. Blue-
green algae such as A. flos aquae marketed as dietary
supplements are commonly grown in open, natural envi-
ronments which allows for possible contamination with
toxin-producing cyanobacteria. A. flos aquae has the abil-
ity to produce a multitude of toxins including anatoxin-a,
saxitoxins, cylindrospermospin, and BMAA, in addition to
microcystins [5]. More importantly, microcystins have
been identified as common contaminants of algae dietary
supplements [5]. With over 100 MC congeners identified
and named according to variable amino acids positions,
complete evaluation of supplements or algal material for
all congeners is not feasible [10, 11]. Current methods for
detecting MCs range from simple biological based screen-
ing methods to more complex analytical techniques such
as mass spectrometry [16]. Many of the commonly used
biological detection methods are not congener specific
and therefore may not accurately reflect the true toxic na-
ture of the sample being tested. In addition, the ability of
these techniques to identify all the various MC congeners
is hampered by the lack of standard reference materials
for the toxins. The most consistently identified microcys-
tin, MC-LR, is also believed to be the most potent con-
gener. MC-LR was identified in the supplement along
with MC-LA. MCs cause hepatic necrosis by covalently
binding to the catalytic domains of protein phosphatases
type 1 and 2A, ultimately inhibiting their activity [17].
Hepatic necrosis following exposure to microcystins has
been documented in humans, mice, rats, guinea pigs,
sheep, cattle and dogs [18–22]. Post-mortem, MCs poi-
soning is characterized by severe gross hepatomegaly with
progressive centrilobular hepatocyte necrosis, rounding
and dissociation. Subsequent breakdown of the sinusoidal
endothelium results in intrahepatic hemorrhage and rap-
idly ensuing death [20]. Histopathology was not per-
formed in this case because the dog was coagulopathic.
The dramatic increase in ALT activity and development of
a coagulopathy following a few weeks of exposure to the
dietary supplement support the diagnosis of a hepato-
pathy and likely underlying hepatic necrosis. Fortu-
nately, there was complete resolution of these changes
after cessation of supplement exposure indicating that
the damage is reversible if recognized before complete
hepatic failure ensues.
Although a vast amount of information exists on the
acute toxicity of microcystins, chronic toxicity data is
lacking. The acute, single dose LD50 for the various
microcystins ranges from 43 μg/kg to 11 mg/kg depend-
ing on the congener, species affected and route of
administration. For example, the oral LD50 for MC-LR
in mice is 10.9 mg/kg versus the intraperitoneal LD50 of
43 μg/kg [23, 24]. Most of the commonly identified con-
geners, such as MC-LA and MC-YR, have a similar LD50
range as MC-LR. However, when analyzing for the pres-
ence of microcystins in a diagnostic case, not all the
congeners are tested for. Thus, the true toxicity of the
microcystins may be underestimated. In the current
case, the supplement was analyzed for the presence of
microcystins LR, LA, YR and RR. Both MC-LR and MC-
LA were identified with an estimated amount of 166 ng/g
MC-LR and 962 ng/g MC-LA. Giving the recommended
1 scoop (1 gram) containing 166 ng/g of MC-LR and
962 ng/g of MC-LA, an 8.95 kg dog would consume on
average 0.0185 μg/kg/day of MC-LR and 0.107 μg/kg/day
of MC-LA. Total daily microcystin intake from supple-
ment use was estimated to be 0.126 μg/kg/day. The World
Health Organization has set the tolerable daily intake for
human ingestion of MC-LR at 0.04 μg/kg/day [25], yet no
such tolerance exists for canines or other animals. The
presence of high concentrations of MC-LA, whose hep-
atotoxicity is similar to MC-LR, contributed significantly
to the development of the hepatopathy in this dog. In
addition, due to the limitation of available reference stan-
dards for other microcystin congeners, it is conceivable
that the supplement contained congeners other than MC-
LR and MC-LA.
Increased serum activities of enzymes indicative of he-
patocellular damage have been noted in both acute and
chronic microcystin toxicity studies [20, 26–29]. In
addition, prolonged sub-lethal exposure to MC-LR has
been shown to result in several hepatotoxic effects in-
cluding increased serum activity of hepatic enzymes, de-
creased hepatic protein phosphatase type 1 and 2A
activity and histologically, hepatocellular vacuolization
and apoptosis [26]. The dog in the current case also
showed biochemical evidence indicative of hepatocellu-
lar damage and dysfunction likely induced by prolonged
exposure to microcystins in the dietary supplement. On
Day 14, two weeks after stopping the use of the supple-
ment, there was still evidence of liver dysfunction. More
importantly, complete resolution of the hepatopathy was
detected on Day 40. Recovery has also been shown to be
possible in mice following one month of exposure to a
sublethal concentration of MC-LR [30, 31]. Similar to
the dog in the current case, it took more than 30 days
for complete resolution of the biochemical alterations
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induced by the exposure to MC-LR in mice. Interest-
ingly, hepatic lesions consisting of hepatocellular dis-
array and loss of hepatic architecture were for the most
part reversed 60 days after a month-long exposure to
MC-LR in mice. Although biopsy of the liver was not
attempted in the current case during or after exposure
to MC-LR and MC-LA for comparison, we can only as-
sume structural recovery also occurred in this dog. Had
the dog continued to receive the dietary supplement,
long-term health effects following chronic exposure may
have ensued such as nephrotoxicity and tumor promo-
tion which have been documented in long-term adminis-
tration studies [32, 33].
At the time of presentation, additional differentials such
as infectious (leptospirosis, bacterial), non-infectious in-
flammatory (hepatitis, cirrhosis), copper associated hepato-
pathy, toxin exposure, and neoplasia were all considered.
Complete resolution of the patient’s hepatopathy following
hospitalization suggested that neoplasia, copper associated
hepatopathy, and non-infectious inflammatory differentials
were unlikely. Historical initiation of the blue-green algae
supplement prior to development of clinical and biochem-
ical abnormalities and subsequent testing of the supple-
ment confirming the presence of hepatotoxic microcystins
confirmed the diagnosis of hepatopathy due to toxin ex-
posure. Blue-green algae toxicosis is usually a result of
drinking contaminated water or accidently drinking water
while swimming [18, 34]. This is the first documented case
of blue-green algae intoxication in a dog from ingestion of
a dietary supplement. Blue-green algae products and other
dietary supplements are regulated by the FDA; however,
under the 1994 DSHEA, manufacturers of dietary supple-
ments can market their products without having to dem-
onstrate product safety [35]. Therefore, the dietary
supplement industry is largely self-regulated, relying on in-
formation provided by the actual manufacturers or to the
FDA about contamination or adverse events after use.
Many consumers and animal owners believe that these
products can only be sold if they are safe for use. Unfortu-
nately, the opposite has been demonstrated in several stud-
ies showing the contamination of blue-green algae dietary
supplements with microcystins [5, 7, 9]. The absolute pur-
ity of any blue-green algae product, including the absence
of contamination with hepatotoxic microcystins, cannot be
assured and thus, consumers and pet owners should err on
the side of caution when purchasing and using these
products.
Conclusions
To the authors’ knowledge, this is the first case report of
microcystin intoxication in a dog after using a commer-
cially available blue-green algae dietary supplement.
Consumers as well as veterinarians should recognize the
potential harm in using these supplements. If adverse
effects are noted, cessation of the product is recom-
mended along with supportive care. In addition, more
prudent oversight of dietary supplement use is recom-
mended for our companion animals to prevent adverse
events/intoxications.
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